As a pharmaceutical company, we have a legal responsibility to monitor the safety of all products we market and distribute. Despite Yemen being in the early stages of implementing a pharmacovigilance system and having a minimal ADR reporting and monitoring program, we at Mohammed Mahdi Al-Shaer Corporation apply consistent pharmacovigilance principles across our entire product portfolio.
We have a well-established Standard Operating procedure for Pharmacovigilance and a dedicated PV officer along with an assistant available 24/7. Our pharmacovigilance team is highly qualified and adequately trained to fulfill their responsibilities. Additionally, all our medical and sales representatives are well-trained to handle pharmacovigilance reports effectively.
We encourage healthcare professionals, patients, and other stakeholders to report any suspected side effects or adverse events. Timely and accurate reporting helps us ensure the safety and effectiveness of the products we commercialize. Reports can be made through the following channels:
All the information you share with us will be protected and kept confidential under the applicable laws. The information provided will be used for the purpose of drug safety surveillance and it may be shared with health authorities and the respective manufacturer as mandated. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.
Al-Shaer Corp’s Pharmacovigilance Department
Email 1: pv@al-shaercorp.com
Email 2: taghreed@al-shaercorp.com
Landline: +96701 614401
Mobile: +967 781444636
National Pharmacovigilance Center
Website: sbd-ye.org/index.php/relates-sites/drug-awareness.html
Email: ypc@sbd-ye.org
Landline: +967 01221475
PV Officer: Dr. Taghreed Alnajjar
Landline: +96701 614401
Mobile Number: +967781444636
E-mail: ypc@sbd-ye.org
Landline: 01221475
Mobile Numbers: 733651786/ 770210538
